| Code | CSB-RA011590MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Cendakimab, targeting interleukin-13 (IL-13), a key type 2 cytokine involved in allergic and inflammatory responses. IL-13 plays a central role in the pathogenesis of various type 2 inflammatory diseases by promoting IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and tissue remodeling. This cytokine is critically implicated in asthma, atopic dermatitis, eosinophilic esophagitis, and other allergic conditions, making it an important therapeutic target for understanding disease mechanisms.
Cendakimab is a humanized IgG4 monoclonal antibody that specifically binds to IL-13, blocking its interaction with IL-13 receptors and neutralizing its biological activity. This biosimilar antibody serves as a valuable research tool for investigating IL-13-mediated signaling pathways, evaluating type 2 immune responses, and studying the role of this cytokine in inflammatory disease models. It enables researchers to explore therapeutic mechanisms and conduct preclinical studies in immunology and respiratory disease research.
There are currently no reviews for this product.